Concourse Financial Group Securities, Inc. Intellia Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.67 Billion
- Q4 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 5,216 shares of NTLA stock, worth $55,811. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,216
Previous 3,047
71.18%
Holding current value
$55,811
Previous $62,000
3.23%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
91MCall Options Held
1MPut Options Held
728K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$134 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$109 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$103 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$55.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$40.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $813M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...